Short Interest: Tearlab Corporation (NASDAQ:TEAR) Has Decline in Shorts

November 17, 2016 - By Ellis Scott   ·   0 Comments

Short Interest: Tearlab Corporation (NASDAQ:TEAR) Has Decline in Shorts

The stock of Tearlab Corporation (NASDAQ:TEAR) registered a decrease of 2.89% in short interest. TEAR’s total short interest was 605,400 shares in November as published by FINRA. Its down 2.89% from 623,400 shares, reported previously. With 25,300 shares average volume, it will take short sellers 24 days to cover their TEAR’s short positions. The short interest to Tearlab Corporation’s float is 1.39%. About 701 shares traded hands. TearLab Corp (NASDAQ:TEAR) has declined 18.31% since April 15, 2016 and is downtrending. It has underperformed by 22.93% the S&P500.

TearLab Corporation is an in-vitro diagnostic company. The company has a market cap of $31.89 million. The Firm has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. It currently has negative earnings. The Company, through its subsidiary TearLab Research, Inc., develops technologies to enable eye care practitioners to test a range of biomarkers at the point-of-care.

Insitutional Activity: The institutional sentiment increased to 1.25 in 2016 Q2. Its up 0.62, from 0.63 in 2016Q1. The ratio is positive, as 7 funds sold all TearLab Corp shares owned while 5 reduced positions. 6 funds bought stakes while 9 increased positions. They now own 20.33 million shares or 89.74% more from 10.72 million shares in 2016Q1.
Toronto Dominion Bank & Trust has 0% invested in the company for 3,766 shares. Jp Marvel Advsrs Ltd has invested 0.04% of its portfolio in TearLab Corp (NASDAQ:TEAR). Perkins Management holds 1.29% of its portfolio in TearLab Corp (NASDAQ:TEAR) for 1.76 million shares. Financial Bank Of New York Mellon accumulated 40,266 shares or 0% of the stock. Deutsche Fincl Bank Ag has 0% invested in the company for 15,283 shares. Sio Mgmt Ltd Liability has 635,442 shares for 0.21% of their US portfolio. Financial Bank Of Montreal Can owns 20 shares or 0% of their US portfolio. Moreover, Savings Bank Of America De has 0% invested in TearLab Corp (NASDAQ:TEAR) for 336 shares. Altrinsic Glob Advsr Limited Liability Company has 0.05% invested in the company for 3.04M shares. First Light Asset Mngmt Ltd Liability Company accumulated 3.76M shares or 1.12% of the stock. Chilton Inv Communication Ltd Com reported 1.26M shares or 0.03% of all its holdings. Wells Fargo & Company Mn, a California-based fund reported 5,600 shares. Wall Street reported 658,300 shares or 0.17% of all its holdings. Moreover, State Street Corporation has 0% invested in TearLab Corp (NASDAQ:TEAR) for 16,300 shares. Blackrock Fund Advsrs last reported 15,480 shares in the company.

TearLab Corp (NASDAQ:TEAR) Ratings Coverage

Out of 3 analysts covering Tearlab Corporation (NASDAQ:TEAR), 2 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 67% are positive. Tearlab Corporation has been the topic of 4 analyst reports since August 7, 2015 according to StockzIntelligence Inc. Roth Capital downgraded TearLab Corp (NASDAQ:TEAR) on Thursday, August 4 to “Neutral” rating. The firm has “Strong Buy” rating given on Wednesday, March 9 by Feltl & Co.

TEAR Company Profile

TearLab Corporation, incorporated on June 5, 2002, is an in-vitro diagnostic company. The Firm has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc., develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care.

Another recent and important TearLab Corp (NASDAQ:TEAR) news was published by Marketwatch.com which published an article titled: “TearLab Corp.” on December 21, 2009.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Ellis Scott


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>